Interim results from the DEPROMP trial including the first 100 patients found that the addition of PSMA-PET/CT to mpMRI-guided prostate biopsy increased the detection of csPCa by 4% and found a 2% decrease in non-clinically significant prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.